Skip to content
ATRAAtara Biotherapeutics, Inc.

Earnings

When Atara Biotherapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

53 quarters. Sep 30, 2013 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 15, after the close

Mon, Mar 15, 2027in 117 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 23 – Mar 19

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$1.60M
Revenue, change from a year earlier: Q3 2026 −64.6%, Q2 2026 −96.4%, Q1 2026 −99.5%, Q4 2025 −95.1%
Net income
-$3.41M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$1.22M−64.6% vs Q3 2025

Latest results

  1. Q3 2026Nov 10, 2026, after the closeThe release0.4%by the close of Nov 11
    Revenue
    $1.22M
    −64.6%
    Net income
    -$2.23M
    N/M
    EPS
    -$0.15
    N/M
    Atara reported a net loss of $2.2 million, or ($0.15) basic and diluted loss per share, for the third quarter 2026, as compared to net loss of $4.3 million, or ($0.32) basic and diluted loss per share, for the same period in 2025.
  2. Q2 2026Aug 12, 2026, after the closeThe release6.0%by the close of Aug 13
    Revenue
    $630.00K
    −96.4%
    Net income
    -$4.83M
    N/M
    EPS
    -$0.32
    N/M
  3. Q1 2026May 12, 2026, after the close+6.8%by the close of May 13
    Revenue
    $516.00K
    −99.5%
    Net income
    -$4.15M
    N/M
    EPS
    -$0.29
    N/M
  4. Q4 2025Mar 16, 2026, after the closeThe release10.9%by the close of Mar 17
    Revenue
    $1.60M
    −95.1%
    Net income
    -$3.41M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 10, 2026 · after-hoursNov 10, 202641 d10-Q$1.22M−64.6%-$0.150.4%
Q2 2026Jun 30, 2026Aug 12, 2026 · after-hoursAug 12, 202643 d10-Q$630.00K−96.4%-$0.326.0%
Q1 2026Mar 31, 2026—May 12, 202642 d10-Q$516.00K−99.5%-$0.29+6.8%
FY 2025
Q4 2025derivedDec 31, 2025Mar 16, 2026 · after-hoursMar 16, 202675 d10-K$1.60M−95.1%—10.9%
Q3 2025Sep 30, 2025Nov 11, 2025 · after-hoursNov 12, 202543 d10-Q$3.45M−91.4%-$0.320.4%
Q2 2025Jun 30, 2025Aug 11, 2025 · after-hoursAug 11, 202542 d10-Q$17.58M−38.6%$0.19+7.5%
Q1 2025Mar 31, 2025May 14, 2025 · after-hoursMay 15, 202545 d10-Q$98.15M+258.8%$3.50+14.9%
FY 2024
Q4 2024derivedDec 31, 2024Mar 7, 2025 · after-hoursMar 7, 202566 d10-K$32.75M+670.3%—8.6%
Q3 2024Sep 30, 2024Nov 12, 2024 · after-hoursNov 12, 202443 d10-Q$40.19M+1,779.8%-$2.93+22.9%
Q2 2024Jun 30, 2024Aug 12, 2024 · after-hoursAug 12, 202443 d10-Q$28.64M+2,892.7%-$3.10—
Q1 2024Mar 31, 2024May 9, 2024 · after-hoursMay 9, 202439 d10-Q$27.36M+2,131.4%-$5.65+10.9%
Earlier years, FY 2013 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 10, 2026125192
10-QAug 12, 2026346885
10-QMay 12, 2026219482
10-KMar 16, 2026108361
10-QNov 12, 2025276219
10-QAug 11, 2025106550
10-QMay 15, 2025072040
10-KMar 7, 2025035507
10-QNov 12, 2024125389
10-QAug 12, 2024095533

Provenance

ProvenanceData status and checks

Atara Biotherapeutics, Inc. · CIK 1604464 · Engraved from SEC EDGAR